Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

As earnings season begins, filings to the SEC point to uncertainty from the current administration as potential trouble for ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

The Nasdaq Composite was also down 2.7% for the week, while the Dow Jones Industrial Average declined nearly 2.5%. Still, the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs, ...

A federal judge ended compounding pharmacies’ ability to make copies of the weight loss and diabetes drugs Zepbound and ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.

A U.S. federal judge has restricted compounding pharmacies from making copies of Eli Lilly's weight-loss and diabetes drugs due to a lawsuit against the FDA's decision that there's no longer a ...